PL369005A1 - Kombinacje obejmujące inhibitory enzymu COX-2 i aspirynę - Google Patents

Kombinacje obejmujące inhibitory enzymu COX-2 i aspirynę

Info

Publication number
PL369005A1
PL369005A1 PL02369005A PL36900502A PL369005A1 PL 369005 A1 PL369005 A1 PL 369005A1 PL 02369005 A PL02369005 A PL 02369005A PL 36900502 A PL36900502 A PL 36900502A PL 369005 A1 PL369005 A1 PL 369005A1
Authority
PL
Poland
Prior art keywords
aspirin
cox
inhibitors
combinations
Prior art date
Application number
PL02369005A
Other languages
English (en)
Inventor
Alberto Gimona
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL369005A1 publication Critical patent/PL369005A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02369005A 2001-10-11 2002-10-10 Kombinacje obejmujące inhibitory enzymu COX-2 i aspirynę PL369005A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124459.9A GB0124459D0 (en) 2001-10-11 2001-10-11 Organic compounds

Publications (1)

Publication Number Publication Date
PL369005A1 true PL369005A1 (pl) 2005-04-18

Family

ID=9923664

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02369005A PL369005A1 (pl) 2001-10-11 2002-10-10 Kombinacje obejmujące inhibitory enzymu COX-2 i aspirynę

Country Status (19)

Country Link
US (2) US20040235802A1 (pl)
EP (1) EP1435968A1 (pl)
JP (1) JP2005505606A (pl)
KR (1) KR20040044891A (pl)
CN (1) CN1625405A (pl)
AU (1) AU2006249254A1 (pl)
BR (1) BR0213181A (pl)
CA (1) CA2458981A1 (pl)
CO (1) CO5570661A2 (pl)
GB (1) GB0124459D0 (pl)
HU (1) HUP0401854A2 (pl)
IL (1) IL160620A0 (pl)
MX (1) MXPA04003365A (pl)
NO (1) NO20041432L (pl)
NZ (1) NZ532158A (pl)
PL (1) PL369005A1 (pl)
RU (1) RU2004114560A (pl)
WO (1) WO2003033001A1 (pl)
ZA (1) ZA200401302B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
IL164222A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
AU2003248642A1 (en) 2002-06-11 2003-12-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
CN1914149A (zh) * 2004-01-27 2007-02-14 默克弗罗斯特公司 用于治疗处于血栓形成心血管事件危险中的患者的环氧合酶－2为媒的疾病或状况的组合治疗
EP1888045B1 (en) * 2005-05-24 2010-09-08 Flamel Technologies Oral pharmaceutical composition for treating a cox-2 mediated condition
WO2007012019A2 (en) * 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20100297224A1 (en) * 2006-08-31 2010-11-25 Horizon Therapeutics, Inc. NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US11696894B2 (en) * 2013-12-17 2023-07-11 Celsprin Llc Sequential administration of partitioned absorption aspirin or active aspirin derivative and COX-2 inhibitor
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US10272107B2 (en) * 2017-09-05 2019-04-30 Kenneth O. Russell Method for treating inflammatory brain disorders and traumatic brain injury
US10586872B2 (en) * 2018-07-03 2020-03-10 International Business Machines Corporation Formation of wrap-around-contact to reduce contact resistivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid

Also Published As

Publication number Publication date
HUP0401854A2 (hu) 2004-12-28
US20080027032A1 (en) 2008-01-31
MXPA04003365A (es) 2004-07-23
US20040235802A1 (en) 2004-11-25
BR0213181A (pt) 2004-08-31
CO5570661A2 (es) 2005-10-31
RU2004114560A (ru) 2005-05-20
NZ532158A (en) 2006-04-28
EP1435968A1 (en) 2004-07-14
WO2003033001A1 (en) 2003-04-24
IL160620A0 (en) 2004-07-25
NO20041432D0 (no) 2004-04-05
AU2006249254A1 (en) 2007-01-04
ZA200401302B (en) 2005-01-04
JP2005505606A (ja) 2005-02-24
NO20041432L (no) 2004-06-28
KR20040044891A (ko) 2004-05-31
GB0124459D0 (en) 2001-12-05
CA2458981A1 (en) 2003-04-24
CN1625405A (zh) 2005-06-08

Similar Documents

Publication Publication Date Title
SI1251848T1 (en) Gyrase inhibitors and uses thereof
MXPA03005298A (es) Inhibidores de girasa y usos de los mismos.
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
IL160620A0 (en) Combinations comprising cox-2 inhibitors and aspirin
PL374598A1 (pl) Inhibitory kaspazy i ich zastosowania
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
AU4217201A (en) Tri-aryl-substituted-ethane pde4 inhibitors
GB0114014D0 (en) Compostion and use
EP1434772A4 (en) CONNECTIONS AND METHODS
GB2376073B (en) Fluid-gauging systems and methods
IL172752A0 (en) Cox-2 and faah inhibitors
GB0229834D0 (en) Target and method
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2002359694A8 (en) Compounds and methods
PL363544A1 (pl) Nowe pochodne piperazynowe
GB0224734D0 (en) Construction and elongate members therefor
ZA200306331B (en) Piperazinylcarbonylquinolines and isoquinolines
EP1379240A4 (en) CONNECTIONS AND METHODS
EP1367123A4 (en) NEUROTONIN AND ITS USE
GB0220776D0 (en) FOXP2 and uses thereof
AU2003267790A8 (en) Lipase inhibitors and uses thereof
GB0109278D0 (en) Enzyme inhibitors
GB0106063D0 (en) Libraries and their use
AU2002363187A1 (en) Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
AU2002223649A1 (en) Vegh inhibitors and their use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)